Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

328 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cost-Based Price Calculation of Mexiletine for Nondystrophic Myotonia.
van den Berg S, van der Wel V, de Visser SJ, Stunnenberg BC, Timmers L, van der Ree MH, Postema PG, Hollak CEM. van den Berg S, et al. Among authors: hollak cem. Value Health. 2021 Jul;24(7):925-929. doi: 10.1016/j.jval.2021.02.004. Epub 2021 Apr 10. Value Health. 2021. PMID: 34243835 Free article.
Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance.
Smid BE, van der Tol L, Cecchi F, Elliott PM, Hughes DA, Linthorst GE, Timmermans J, Weidemann F, West ML, Biegstraaten M, Lekanne Deprez RH, Florquin S, Postema PG, Tomberli B, van der Wal AC, van den Bergh Weerman MA, Hollak CE. Smid BE, et al. Int J Cardiol. 2014 Dec 15;177(2):400-8. doi: 10.1016/j.ijcard.2014.09.001. Epub 2014 Sep 20. Int J Cardiol. 2014. PMID: 25442977 Review.
Continued misuse of orphan drug legislation: a life-threatening risk for mexiletine.
Postema PG, Schwartz PJ, Arbelo E, Bannenberg WJ, Behr ER, Belhassen B, Brugada J, Brugada P, John Camm A, Casado-Arroyo R, 't Hoen E, Hollak CEM, Kääb S, Lambiase PD, Leenhardt A, Priori SG, Probst V, Stunnenberg BC, Tfelt-Hansen J, Van Engelen BGM, Veltmann C, Viskin S, Wilde AAM. Postema PG, et al. Among authors: hollak cem. Eur Heart J. 2020 Feb 1;41(5):614-617. doi: 10.1093/eurheartj/ehaa041. Eur Heart J. 2020. PMID: 32006435 No abstract available.
Registries for orphan drugs: generating evidence or marketing tools?
Hollak CEM, Sirrs S, van den Berg S, van der Wel V, Langeveld M, Dekker H, Lachmann R, de Visser SJ. Hollak CEM, et al. Orphanet J Rare Dis. 2020 Sep 3;15(1):235. doi: 10.1186/s13023-020-01519-0. Orphanet J Rare Dis. 2020. PMID: 32883346 Free PMC article.
Drug Repurposing for Rare Diseases: A Role for Academia.
van den Berg S, de Visser S, Leufkens HGM, Hollak CEM. van den Berg S, et al. Among authors: hollak cem. Front Pharmacol. 2021 Oct 20;12:746987. doi: 10.3389/fphar.2021.746987. eCollection 2021. Front Pharmacol. 2021. PMID: 34744726 Free PMC article.
Author Reply.
van den Berg S, de Visser SJ, Timmers L, Hollak CEM. van den Berg S, et al. Among authors: hollak cem. Value Health. 2022 Jan;25(1):158-159. doi: 10.1016/j.jval.2021.08.005. Epub 2021 Sep 21. Value Health. 2022. PMID: 35031095 Free article. No abstract available.
Modified Delphi procedure-based expert consensus on endpoints for an international disease registry for Metachromatic Leukodystrophy: The European Metachromatic Leukodystrophy initiative (MLDi).
Schoenmakers DH, Beerepoot S, van den Berg S, Adang L, Bley A, Boelens JJ, Fumagalli F, Goettsch WG, Grønborg S, Groeschel S, van Hasselt PM, Hollak CEM, Lindemans C, Mochel F, Mol PGM, Sevin C, Zerem A, Schöls L, Wolf NI. Schoenmakers DH, et al. Among authors: hollak cem. Orphanet J Rare Dis. 2022 Feb 14;17(1):48. doi: 10.1186/s13023-022-02189-w. Orphanet J Rare Dis. 2022. PMID: 35164810 Free PMC article.
328 results